Study flags need to monitor frailty risks with GLP-1 drugs for older adults

• Among tirzepatide users who developed malnutrition, the risk of death increased 25-fold compared to users without malnutrition, versus 7-fold for other diabetes drugs and 2-fold for bariatric surgery patients
• The study analyzed nearly 30,000 adults age 65+ on Zepbound and found frailty conditions emerged in small percentages: 0.16% had muscle decline, 1.6% malnutrition, 3% dehydration, and 4.75% appetite loss, typically appearing after six months of treatment
• Researchers recommend aggressive intervention when frailty signals appear, including potentially stopping tirzepatide and increasing monitoring, though they emphasize the drug should not be avoided as the study does not prove causation

Summary: Study Highlights Frailty Monitoring Needs for GLP-1 Drugs in Older Adults

A large study released July 14 by U.S. data analytics firm nference raises concerns about frailty-related risks in seniors using GLP-1 obesity medications, particularly Eli Lilly's Zepbound (tirzepatide). The research, submitted for peer review, examined nearly 30,000 adults age 65+ treated with Zepbound, comparing them to 19,000 non-GLP-1 diabetes drug users and 6,000 bariatric surgery patients.

Key Findings:

While frailty conditions developed rarely overall—malnutrition (1.6%), dehydration (3%), loss of appetite (4.75%), and muscle decline (0.16%)—tirzepatide users who developed these conditions faced significantly elevated mortality risks. Malnutrition increased death risk 25-fold for tirzepatide users versus 7-fold for other diabetes treatments and 2-fold for surgery patients. Dehydration raised mortality risk 6-fold with tirzepatide compared to 4-fold and 2.5-fold respectively. Muscle wasting increased death risk 12-fold in tirzepatide users.

These frailty signals typically emerged after six months of treatment. Researchers emphasize the findings don't prove causation but suggest underlying health deterioration requiring aggressive intervention and monitoring.

Market Context:

The study arrives as Medicare expanded GLP-1 obesity drug coverage starting July 1, 2026, with $50 monthly copays potentially reaching 3-4 million eligible seniors. Over 41% of U.S. adults 60+ are obese, representing significant market opportunity for Eli Lilly and Novo Nordisk's Wegovy (semaglutide).

Expert Recommendations:

Researchers advocate closer monitoring rather than avoiding these effective treatments. UCLA endocrinologist Dr. Preethi Srikanthan suggests prospective studies on resistance exercise and protein supplementation to prevent functional decline. Eli Lilly did not immediately comment.